Hinge Health CEO Daniel Perez Talks One Year Since Its Trading Debut on NYSE

Why It Matters

Hinge’s combination of improving unit economics, fast cash-flow growth and FDA-cleared device rollout signals a scalable digital-care model that could cut employer and payer costs and capture a meaningful slice of a large, under-digitized healthcare services market. The migraine push and ambition to automate care broaden revenue sources and heighten the company’s strategic importance to clients seeking value-based alternatives.

Summary

Hinge Health marked its first year as a public company with its stock up about 72% since listing, reporting roughly 50% year-over-year revenue growth and a tenfold increase in free cash flow as it adds hundreds of new corporate clients. CEO Daniel Perez said the business remains focused on scalable digital musculoskeletal care that reduces downstream costs like surgery and imaging, while maintaining strong clinical outcomes. The company has broadened its product suite into migraine treatment after receiving FDA clearance for its Enzo wearable electrical nerve stimulation device and has already deployed it to hundreds of members and customers. Perez emphasized a long runway for expansion across musculoskeletal care, neurology and other healthcare services, noting Hinge currently captures about 1% of the PT market and a fraction of total U.S. healthcare spend.